Kauzmasa Oya

Dr. Kauzmasa Oya

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KOKauzmasa Oya
Kauzmasa Oya
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
ZZZHU ZHENJIE
ZHU ZHENJIE
RTRyota Tanaka
Ryota Tanaka
NONaoko Okiyama
Naoko Okiyama
YFYasuhiro Fujisawa
Yasuhiro Fujisawa
The exact mechanisms of the imiquimod (IMQ)-induced antitumor effect have not been fully understood. Although both topical IMQ treatment and anti-PD-1 antibody may be used for primary skin lesions or skin metastases of various cancers, the efficacy of each monotherapy for these lesions is insufficient. Using a murine tumor model and human samples, we aimed to elucidate the detailed mechanisms of the IMQ-induced antitumor effect and analyzed the antitumor effect of combination therapy of topical IMQ plus anti-PD-1 antibody. Topical IMQ significantly suppressed the tumor growth of MC38 in wildtype mice. IMQ upregulated interferon γ (IFN-γ) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-γ-deficient mice, indicating that IFN-γ produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect. IMQ also upregulated PD-1 expression in T cells as well as PD-L1/PD-L2 expression in myeloid cells, suggesting that IMQ induces not only T-cell activation but also T-cell exhaustion by enhanced PD-1 inhibitory signaling. Combination therapy of topical IMQ plus anti-PD-1 antibody exerted a significantly potent antitumor effect when compared with each single therapy, indicating that the combination therapy is a promising therapy for the skin lesions of various cancers.

3 March 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
KOKauzmasa Oya
Kauzmasa Oya
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
LSLarina TzuWei Shen
Larina TzuWei Shen
SIShoichiro Ishizuki
Shoichiro Ishizuki
SMSatoshi Matsusaka
Satoshi Matsusaka
YFYasuhiro Fujisawa
Yasuhiro Fujisawa

13 July 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
KOKauzmasa Oya
Kauzmasa Oya
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
KIK. Iwamoto
K. Iwamoto
TKT. Kimura
T. Kimura
HNH. Negoro
H. Negoro
YFYasuhiro Fujisawa
Yasuhiro Fujisawa

7 July 2017 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KOKauzmasa Oya
Kauzmasa Oya
MFMasanao Fujii
Masanao Fujii
STShijima Taguchi
Shijima Taguchi
WNWataru Nishie
Wataru Nishie
KIKentaro Izumi
Kentaro Izumi
HSHiroshi Shimizu
Hiroshi Shimizu

5 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
KOKauzmasa Oya
Kauzmasa Oya
LSLarina TzuWei Shen
Larina TzuWei Shen
KMKazushi Maruo
Kazushi Maruo
SMSatoshi Matsusaka
Satoshi Matsusaka
The antitumor effect of antibody-drug conjugates (ADC) is the main factor in achieving cures. Although the mechanism of tumor resistance to treatment is multifaceted, tumor-derived extracellular vesicles (T-EVs) have been implicated as contributing to the attenuation of ADC therapeutic efficacy. Thus, strategies to eliminate T-EVs are highly promising for overcoming drug resistance. Here we demonstrate plasma exchange therapy to remove T-EVs, decreasing their amount in vitro by 75%. Although trastuzumab emtansine (T-DM1) treatment alone was effective in our rat tumor model, the combination therapy of T-DM1 and T-EV filtration achieved early tumor shrinkage. Our results indicate that T-EV filtration plus ADC is a promising strategy for overcoming drug resistance.

15 May 2021 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
KOKauzmasa Oya
Kauzmasa Oya
MFMasanao Fujii
Masanao Fujii
STShijima Taguchi
Shijima Taguchi
Click on the article title to read more.